COVID-19 and emerging viral infections: The case for interferon lambda

2020207 citationsJournal Articlebronze Open Access

Authors

Ludmila Prokunina‐Olsson · National Cancer Institute

Noémie Alphonse · King's College London

Ruth E. Dickenson · King's College London

Joan E. Durbin · Rutgers, The State University of New Jersey

Jeffrey S. Glenn · Palo Alto Veterans Institute for Research

Rune Hartmann · Aarhus University

Sergei V. Kotenko

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Topics & Keywords

COVID-19 Clinical Research Studies interferon and immune responses SARS-CoV-2 and COVID-19 Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Experimental Medicine

Volume 217, Issue 5

DOI: 10.1084/jem.20200653

Field-Weighted Citation Impact: 4.86